Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)Pk-11195 SCHEMBL15118334 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| Pk-11195 SCHEMBL117124 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL29357086 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL12790424 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| Pk-11195 SCHEMBL29354252 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL3126094 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL29477174 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| Pk-11195 SCHEMBL31060347 | 1.00 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3046732 | 0.89 | TSPO (0.81) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3035734 | 0.89 | TSPO (0.81) | TSPOMEN1KMT2ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2001-12-13 | — | — | US | claimed |
| EP-0953356-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | claimed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-6417220-B2 | A MEDICINE FOR PREVENTIVE/TREATMENT OF DISEASE CAUSED BY MITOCHONDRIAL MEMBRANE DEPOLARIZATION BECAUSE OF ELEVATION OF INTRACELLULAR CALCIUM ION CONCENTRATION; BENZODIAZEPINE RECEPTOR ANTAGONIST, E.G.,NEFIRACETAM; ANTIISCHEMIC AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0953356-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | TFAM, MDH2, NLN | TSPO 23/4885MEN1 3863/4885KMT2A 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.